Skip to main content
Figure 2 | Breast Cancer Research

Figure 2

From: Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy

Figure 2

Basal-like breast tumours do not exhibit amplifications for epidermal growth factor receptor (EGFR) or Y-box binding protein 1 (YB-1). Primary breast tumours were evaluated for genetic amplifications using SMRT array CGH. DNA was isolated from ten primary basal-like breast tumours and genomic profiles were generated by submegabase resolution tiling array comparative genomic hybridisation. There was no obvious gain of copy number on chromosomes 1 or 7, representing the loci for YB-1 and EGFR, respectively. The exception to this trend was BLC9, where there was a large amplicon on chromosome 7. The lung adenocarcinoma cell line HCC827 was included as a positive control of EGFR amplification.

Back to article page